Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E33.52 EPS (ttm)1.83 Insider Own0.04% Shs Outstand2.78B Perf Week-1.51%
Market Cap170.24B Forward P/E15.71 EPS next Y3.90 Insider Trans-41.82% Shs Float2.76B Perf Month-2.89%
Income5.13B PEG5.11 EPS next Q0.98 Inst Own74.60% Short Float1.01% Perf Quarter5.27%
Sales39.44B P/S4.32 EPS this Y-61.60% Inst Trans-0.02% Short Ratio2.73 Perf Half Y10.55%
Book/sh15.66 P/B3.91 EPS next Y4.01% ROA5.20% Target Price66.47 Perf Year21.59%
Cash/sh4.25 P/C14.39 EPS next 5Y6.57% ROE11.60% 52W Range46.83 - 64.86 Perf YTD18.70%
Dividend1.84 P/FCF35.85 EPS past 5Y41.50% ROI6.40% 52W High-5.64% Beta0.73
Dividend %3.01% Quick Ratio1.50 Sales past 5Y-3.00% Gross Margin63.20% 52W Low30.70% ATR1.04
Employees68000 Current Ratio1.90 Sales Q/Q0.60% Oper. Margin18.10% RSI (14)42.64 Volatility1.30% 1.52%
OptionableYes Debt/Eq0.56 EPS Q/Q79.20% Profit Margin13.00% Rel Volume0.73 Prev Close61.92
ShortableYes LT Debt/Eq0.55 EarningsOct 25 BMO Payout99.50% Avg Volume10.17M Price61.20
Recom2.50 SMA20-1.93% SMA50-2.01% SMA2009.26% Volume7,395,151 Change-1.16%
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Oct-22-16 12:01AM  [$$] After a Bumpy Week, Stocks End Up 0.4% at
Oct-21-16 09:57PM  FDA Approves Mercks ZINPLAVA (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence Business Wire
01:00PM  Merck Set For Big Move After 3-Month Slumber (MRK) at Investopedia
11:36AM  Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
10:04AM  Eli Lilly and Co.s 3Q16: The Major Developments
09:44AM  Will Merck Report Another Healthy Quarter?
08:04AM  Eli Lilly and Co.s 3Q16: Expectations for Elanco
06:45AM  Mercks KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early Business Wire
Oct-20-16 05:48PM  Another Health Care Chart Looks Sick
11:04AM  Eli Lilly and Co.s 3Q16 Estimates: Expectations for New Products
08:18AM  Blog Coverage Merck FDA Fast Tracked Antiviral Medicine Hits Phase III Target
08:15AM  Blog Coverage Merck FDA Fast Tracked Antiviral Medicine Hits Phase III Target Accesswire
Oct-19-16 07:26PM  Preteens need only 2 HPV shots _ not 3, CDC says
12:58PM  ETFs with exposure to Merck & Co., Inc. : October 19, 2016
10:27AM  WHO seeks new mechanism for crisis vaccine supplies at low cost Reuters
08:38AM  Key Takeaways from JNJ's Q3 Call: Remicade, Pipeline, Acquisitions
07:00AM  Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint Business Wire
Oct-18-16 05:33PM  Roche's lung cancer drug wins U.S. approval Reuters
05:21PM  Eli Lillys 3Q16 Earnings: What to Expect
Oct-17-16 05:00PM  Merck Research Laboratories Facilities Designated as Milestones in Microbiology Sites by the American Society for Microbiology Business Wire
11:04AM  Johnson & Johnsons Expected Profitability in 3Q16
09:30AM  The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers
Oct-16-16 08:38PM  Buy Merck on Drops to $60
Oct-14-16 06:04PM  How Will Johnson & Johnson Fare Revenue-Wise in 3Q16?
11:32AM  Merck & Co., Inc. : MRK-US: Dividend Analysis : September 15th, 2016 (record date) : By the numbers : October 14, 2016
11:04AM  How Much Is Pfizers Return Potential?
09:57AM  Merck KGaA Offers Portfolio Updates at Market Day Event
09:39AM  Stocks Open Higher As Europe Rallies; JPMorgan, Goldman Sachs Climb
09:22AM  Pharma Stock Roundup: Mylan in EpiPen Medicaid Settlement, ESMO Data in Focus
08:30AM  Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community Business Wire
08:21AM  Competition Fuels Aetna, Merck Deal (AET, MRK) at Investopedia
Oct-13-16 04:17PM  Apple Price Target Raised; Gigamon, GrubHub Rated Buys
04:04PM  Did Pfizers Top Line Growth Beat Its Peers?
02:00PM  Experiment in monkeys raises hopes of "functional cure" for HIV
12:24PM  BofA: Expect upside to Merck estimates
10:07AM  Stocks Extend Losses To 1%; Ulta Beauty Gains
08:55AM  Top Analyst Upgrades and Downgrades: Charles Schwab, Merck, Nokia, Viacom, Waste Management, Windstream and More at 24/7 Wall St.
07:36AM  Merck upgraded by BofA/Merrill
Oct-12-16 03:04PM  Gilead Sciences HCV Portfolio Hurt by Weakening Sales
10:04AM  Merck Publishes First International Curiosity Study PR Newswire
08:04AM  How Large of a Role Does Opdivo Play in Bristol-Myers Squibbs Success?
Oct-11-16 07:07PM  US Market Indexes Lower on Tuesday
03:15PM  Aetna, Merck sign value-based pact for diabetes drugs at
11:04AM  BMY Waiting to Enter the First-Line Lung Cancer Space
10:10AM  Company News for October 11, 2016
10:06AM  How Bristol-Myers Squibb Is Expanding Its Lung Cancer Treatments
08:05AM  Bristol-Myers Squibbs Strategies to Dominate Immuno-Oncology Market
08:04AM  How Did Gileads Other Products Perform in 2Q16?
Oct-10-16 06:18PM  Oil Prices Help Stock Valuations on Monday
04:33PM  How a Merck cancer breakthrough caused Bristol-Myers stock to plunge at MarketWatch
04:30PM  Stocks close higher on oil, energy-sector gains at MarketWatch
04:20PM  Merck Topples Bristol-Myers On Lung Cancer Drug Win
04:14PM  CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10% at Motley Fool
04:12PM  Merck: Promising Results From Immunotherapy Based on Keytruda
04:02PM  Energy Stocks Lead Rally, But S&P 500 Closes Below 50-Day
02:07PM  Mylan soars on EpiPen settlement
01:46PM  Trending Tickers: MRK, BMY, TSRO, TWLO, CRM
12:57PM  Merck Topples Bristol-Myers On Lung Cancer Drug Win
12:35PM  War on cancer
12:03PM  Stocks Solidly Higher Ahead Of Alcoa Earnings, Fed Minutes
12:00PM  Bristol-Myers Squibb's Lost Ground
11:23AM  Stocks rise as oil jumps nearly 3%; US election in focus at CNBC
10:28AM  Dow, S&P 500 Retake 50-Day Line; Merck Rallies On Cancer Drug News
10:25AM  Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment
10:04AM  Bristol Dominates with Multiple Immuno-Oncology Studies
10:04AM  Whats Driving Gileads HIV Drug Portfolio?
09:58AM  Stocks Jump: S&P 500 Retakes 50-Day As Mylan Surges, Twitter Dives
08:04AM  Whats New with Gilead Sciences?
02:49AM  Merck Announces Recipients of Third Annual 1 Million 'Grant for Oncology Innovation' Award CNW Group
02:07AM  Merck Announces Recipients of Third Annual 1 Million 'Grant for Oncology Innovation' Award PR Newswire
Oct-09-16 11:01PM  Sunday Wrap: Tesla's Musk, Alibaba-Spielberg, Opdivo Flop, Samsung Woes
03:30PM  Mindset Shifts Take Time
08:00AM  A new kind of treatment is working better than chemotherapy in some lung cancer patients
07:50AM  Merck Solidifies Lung Cancer Immunotherapy Lead over Bristol-Myers Squibb
02:16AM  Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Mercks KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients Business Wire
02:15AM  KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress Business Wire
02:13AM  [$$] Bristol-Myers lung cancer drug fails to meet immunotherapy hopes at Financial Times
Oct-08-16 11:45AM  The trillion-dollar reason why Wall Street should take gender diversity more seriously
08:45AM  Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress Business Wire
02:15AM  New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients Business Wire
Oct-07-16 04:23PM  Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results
04:05PM  Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine Business Wire
Oct-06-16 05:52PM  Billions at stake for big pharma
01:15PM  Merck & Co. Inc. (MRK) Shuts Down Florida Facility at Insider Monkey
08:12AM  Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good
Oct-05-16 02:52PM  Tune In Sunday For More On Bristol-Myers's Cancer Drug at
10:17AM  FDA Warns on Hepatitis C Drugs at The Wall Street Journal
Oct-04-16 04:10PM  NewLink Genetics Awarded $25 Million Contract from BARDA for Investigational Ebola Zaire Vaccine (V920) GlobeNewswire
11:04AM  Whats the Outlook for Merck & Co.?
10:04AM  A Look at Gardasil and Merck & Co.s Vaccines Business
08:42AM  5 FDA Decisions to Watch Out for in October 2016
Oct-03-16 11:05AM  What Will Drive Novo Nordisks Growth in Diabetes and Hemophilia?
10:06AM  Recent Corporate and R&D Progress for Merck & Co.
08:20AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : October 3, 2016
08:00AM  Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016 Business Wire
Oct-02-16 12:44PM  Passing Inflection Point on Pricing and Profits
Sep-30-16 07:04PM  Understanding Mercks Business Segments and Their Revenue Trends
03:56PM  Novo Nordisk Is Number One Player in Diabetes Care Market in 2016
08:25AM  SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now at 24/7 Wall St.
Sep-29-16 06:59PM  Deutsche Bank's Losses Affecting the Market on Thursday
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM